Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 21, 2026, 8:07 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–19 of 19 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: FGFR2 Fusion Clear all
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Malignant Hepatobiliary Neoplasm
Interventions
Laboratory Biomarker Analysis, Ponatinib Hydrochloride, Quality-of-Life Assessment
Other · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Nov 24, 2020 · Synced May 21, 2026, 8:07 PM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Advanced Cholangiocarcinoma, FGFR2 Fusions, Gene Rearrangement
Interventions
TAS-120
Drug
Lead sponsor
Taiho Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
10
States / cities
La Jolla, California • Tampa, Florida • Detroit, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2025 · Synced May 21, 2026, 8:07 PM EDT
Terminated Phase 2 Interventional Results available
View directory record Official record
Conditions
Advanced Cholangiocarcinoma, FGFR2 Gene Mutation
Interventions
BGJ398 (infigratinib)
Drug
Lead sponsor
QED Therapeutics, a BridgeBio company
Industry
Eligibility
18 Years and older
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
11
States / cities
Phoenix, Arizona • Los Angeles, California • San Francisco, California + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2023 · Synced May 21, 2026, 8:07 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Intrahepatic Cholangiocarcinoma, Combined Hepatocellular and Cholangiocarcinoma
Interventions
derazantinib
Drug
Lead sponsor
Basilea Pharmaceutica
Industry
Eligibility
18 Years and older
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
11
States / cities
Phoenix, Arizona • Jacksonville, Florida • Tampa, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2023 · Synced May 21, 2026, 8:07 PM EDT
Completed Phase 1Phase 2 Interventional Results available
View directory record Official record
Conditions
Solid Tumor
Interventions
Derazantinib low dose range, Derazantinib middle dose range, Derazantinib high dose range, Derazantinib at recommended phase 2 dose (RP2D)
Drug
Lead sponsor
Basilea Pharmaceutica
Industry
Eligibility
18 Years and older
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
8
States / cities
Scottsdale, Arizona • Atlanta, Georgia • Detroit, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2023 · Synced May 21, 2026, 8:07 PM EDT
Recruiting Phase 1 Interventional
View directory record Official record
Conditions
Locally Advanced Cholangiocarcinoma, Intrahepatic Cholangiocarcinoma, Solid Tumor, Metastatic Cholangiocarcinoma
Interventions
Phase 1 Part A - dose escalation TYRA-200 taken once daily by mouth in 28-day cycles, Phase 1 Part B - dose expansion TYRA-200 taken once daily by mouth in 28-day cycles
Drug
Lead sponsor
Tyra Biosciences, Inc
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
4
States / cities
San Francisco, California • Boston, Massachusetts • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2024 · Synced May 21, 2026, 8:07 PM EDT
Completed No phase listed Observational
View directory record Official record
Conditions
Intrahepatic Cholangiocarcinoma, Mixed Hepatocellular Cholangiocarcinoma, Cholangiocarcinoma
Interventions
Not listed
Lead sponsor
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Industry
Eligibility
18 Years and older
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
2
States / cities
Atlanta, Georgia • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 7, 2017 · Synced May 21, 2026, 8:07 PM EDT
Recruiting Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Advanced Cholangiocarcinoma, FGFR2 Fusion
Interventions
Pemigatinib, Atezolizumab, Bevacizumab
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 13, 2026 · Synced May 21, 2026, 8:07 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Advanced Solid Tumors With Alterations of FGFR1, 2 and or 3, Squamous Lung Cancer With FGFR1 Amplification, Bladder Cancer With FGFR3 Mutation or Fusion, Advanced Solid Tumors With FGFR1 Amplication, Advanced Solid Tumors With FGFR2 Amplication, Advanced Solid Tumors With FGFR3 Mutation
Interventions
BGJ398
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
16
States / cities
Duarte, California • Los Angeles, California • Aurora, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2019 · Synced May 21, 2026, 8:07 PM EDT
Terminated Phase 3 Interventional Results available
View directory record Official record
Conditions
Advanced Cholangiocarcinoma, FGFR2 Gene Rearrangements
Interventions
Futibatinib, Cisplatin, Gemcitabine
Drug
Lead sponsor
Taiho Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
8
States / cities
Duarte, California • Louisville, Kentucky • Albuquerque, New Mexico + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2025 · Synced May 21, 2026, 8:07 PM EDT
Terminated Phase 3 Interventional Results available
View directory record Official record
Conditions
Advanced Cholangiocarcinoma, FGFR2 Gene Mutation
Interventions
BGJ398, Gemcitabine, Cisplatin
Drug
Lead sponsor
QED Therapeutics, a BridgeBio company
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
25
States / cities
Gilbert, Arizona • Tucson, Arizona • Little Rock, Arkansas + 17 more
Source: ClinicalTrials.gov public record
Updated May 7, 2024 · Synced May 21, 2026, 8:07 PM EDT
Withdrawn Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Advanced Solid Tumor, CNS Tumor, Recurrent WHO Grade II Glioma
Interventions
Infigratinib
Drug
Lead sponsor
Helsinn Healthcare SA
Industry
Eligibility
3 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
6
States / cities
Palo Alto, California • Washington D.C., District of Columbia • Miami, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2023 · Synced May 21, 2026, 8:07 PM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Advanced Pancreatic Carcinoma, Metastatic Pancreatic Carcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
Interventions
Pemigatinib, Computed Tomography (CT), Magnetic Resonance Imaging, Optical Coherence Tomography, Bone Scan, Ophthalmoscopy
Drug · Procedure
Lead sponsor
Sameek Roychowdhury
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
109
States / cities
Birmingham, Alabama • Mobile, Alabama • Montgomery, Alabama + 106 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2026 · Synced May 21, 2026, 8:07 PM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
FGFR2 Gene Fusion/Rearrangement, Other Solid Tumors, Adult
Interventions
Lirafugratinib
Drug
Lead sponsor
Elevar Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
7
States / cities
Phoenix, Arizona • Jacksonville, Florida • Tampa, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced May 21, 2026, 8:07 PM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Intrahepatic Cholangiocarcinoma, FGFR2 Gene Rearrangement, FGFR2 Gene Mutation
Interventions
Pemigatinib, Durvalumab
Drug
Lead sponsor
Mehmet Akce
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
2
States / cities
Birmingham, Alabama • Buffalo, New York
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced May 21, 2026, 8:07 PM EDT
Terminated Phase 2 Interventional Results available
View directory record Official record
Conditions
Solid Tumor
Interventions
Debio 1347
Drug
Lead sponsor
Debiopharm International SA
Industry
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
25
States / cities
Scottsdale, Arizona • Tucson, Arizona • La Jolla, California + 21 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2024 · Synced May 21, 2026, 8:07 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Intrahepatic Cholangiocarcinoma (Icc), Cholangiocarcinoma, Other Solid Tumors, Adult, FGFR2 Gene Fusion/Rearrangement, FGFR2 Gene Amplification, FGFR2 Gene Short Variants, FGFR3 Gene Fusion/Rearrangement, FGFR3 Gene Amplification, FGFR3 Gene Short Variants, FGFR2 Genetic Alterations, FGFR3 Genetic Alterations, Advanced Solid Tumors
Interventions
CGT4859
Drug
Lead sponsor
Cogent Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
12
States / cities
Palo Alto, California • Jacksonville, Florida • Tampa, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced May 21, 2026, 8:07 PM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Cholangiocarcinoma, FGFR2 Fusion, FGFR2 Gene Mutation, FGFR1 Alteration, FGFR3 Alteration
Interventions
TT-00420
Drug
Lead sponsor
TransThera Sciences (Nanjing), Inc.
Industry
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
32
States / cities
Anchorage, Alaska • Duarte, California • Santa Monica, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2024 · Synced May 21, 2026, 8:07 PM EDT
Completed Phase 1Phase 2 Interventional
View directory record Official record
Conditions
FGFR2 Amplification, FGFR2 Gene Mutation, FGFR2 Gene Fusion/Rearrangement, FGFR2 Gene Translocation, FGFR2 Gene Activation, Intrahepatic Cholangiocarcinoma, Cholangiocarcinoma, Other Solid Tumors, Adult
Interventions
RLY-4008
Drug
Lead sponsor
Elevar Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
490 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
18
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 15 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced May 21, 2026, 8:07 PM EDT